- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Noting Group Differences
Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.
Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.
One recent study, of almost 600,000 people covered by Medicare in three states, found that as a group, people of color were only about half as likely as whites to be screened for colorectal cancer. In addition, women were more likely than men to undergo some type of screening but less likely than men to have a colonoscopy.
The study, published in February in the Archives of Internal Medicine, also found that populations with higher income levels were more likely to undergo a colon screening test than those that were poorer. Yet even after adjusting for the income difference, the scientists, from the Medical College of Wisconsin in Milwaukee, still found that nonwhites had lower screening rates.
That finding, wrote the researchers, “is worrisome because both colon cancer incidence and mortality are higher than in whites.”
Presurgical Opdivo, Chemo See High Response in Early-Stage Breast Cancer
December 9th 2023Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.
Read More
‘The Complete Guide to Breast Reconstruction’ Author Empowers Patients With Information
October 5th 2023Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.
Listen
Consider Endocrine Therapy Responses When Planning Chemo in Breast Cancer Subset
December 9th 2023Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.
Read More
Tecentriq Plus Perjeta, Herceptin, Chemo Does Not Improve pCR in HER2+ Breast Cancer
December 8th 2023A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.
Read More
